| Identification | Back Directory | [Name]
D-Leucine, D-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-cysteinyl-L-α-glutamyl-L-leucyl-L-cysteinyl-L-valyl-L-asparaginyl-L-valyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-, cyclic (4→12),(7→15)-bis(disulfide) | [CAS]
1092457-65-2 | [Synonyms]
Dolcanatide
D-Leucine, D-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-cysteinyl-L-α-glutamyl-L-leucyl-L-cysteinyl-L-valyl-L-asparaginyl-L-valyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-, cyclic (4→12),(7→15)-bis(disulfide) | [Molecular Formula]
C65H104N18O26S4 | [MOL File]
1092457-65-2.mol | [Molecular Weight]
1681.89 |
| Chemical Properties | Back Directory | [Boiling point ]
2120.0±65.0 °C(Predicted) | [density ]
1.47±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
3.61±0.21(Predicted) | [color ]
White to off-white | [Sequence]
{d-Asn}--Asp-Glu-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-{d-Leu} (Disulfide bridge: Cys4-Cys12; Cys7-Cys15) |
| Hazard Information | Back Directory | [Uses]
Dolcanatide is an orally active GC-C (guanylate cyclase-C) agonist. Dolcanatide shows laxative, anti-nociceptive and anti-inflammatory activity. Dolcanatide can be used in inflammatory bowel disease research[1][2]. | [in vivo]
Dolcanatide (oral administration; 0.01 and 0.05 mg/kg; once) alleviates TNBS-induced rectal allodynia in rats[1].
Dolcanatide (oral administration; 0.01 and 0.05 mg/kg; once) alleviates stress-induced colorectal hypersensitivity (CRD) in rats[1]. | Animal Model: | TNBS-induced rectal allodynia in rats[1] | | Dosage: | 0.01 and 0.05 mg/kg | | Administration: | Oral administration; 0.01 and 0.05 mg/kg; once | | Result: | Attenuated the TNBS-induced increase in the number of abdominal contractions (distending pressures up to 60 mmHg). |
| Animal Model: | Stress-induced visceral hypersensitivity in Wistar rats[1] | | Dosage: | 0.01 and 0.05 mg/kg | | Administration: | Oral administration; 0.01 and 0.05 mg/kg; once | | Result: | Resulted in a significant reduction in the rate of PRS (partial restraint stress)-induced abdominal contractions with increasing CRD (colorectal distension) pressures. |
| [References]
[1] Boulete IM, et al. Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models. World J Gastroenterol. 2018 May 7;24(17):1888-1900. DOI:10.3748/wjg.v24.i17.1888
[2] Shailubhai K, et al. Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. World J Gastrointest Pharmacol Ther. 2015 Nov 6;6(4):213-22. DOI:10.4292/wjgpt.v6.i4.213 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|